INT199433

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.17
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.84
Pain Relevance 0.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (LTA) extracellular space (LTA) extracellular region (LTA)
cell-cell signaling (LTA)
Anatomy Link Frequency
cartilage 1
LTA (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 25 98.38 Very High Very High Very High
withdrawal 9 97.04 Very High Very High Very High
corticosteroid 151 96.24 Very High Very High Very High
rheumatoid arthritis 8 96.24 Very High Very High Very High
cytokine 34 91.92 High High
Inflammation 71 89.36 High High
ischemia 4 62.00 Quite High
agonist 8 53.88 Quite High
depression 2 50.00 Quite Low
Antihistamine 2 44.56 Quite Low
Disease Link Frequency Relevance Heat
Syndrome 567 99.54 Very High Very High Very High
Asthma 235 98.12 Very High Very High Very High
Rheumatoid Arthritis 8 96.24 Very High Very High Very High
INFLAMMATION 77 89.36 High High
Renal Disease 12 88.56 High High
Adhesions 4 82.88 Quite High
Recurrence 53 81.68 Quite High
Hypersensitivity 25 81.28 Quite High
Hepatitis C Virus Infection 52 81.24 Quite High
Increased Venous Pressure Under Development 72 79.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
and IL-2, which augment neutrophil-mediated inhibition of cartilage proteoglycan synthesis, LT markedly depressed this activity [30].
Negative_regulation (inhibition) of LT in cartilage
1) Confidence 0.17 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2483446 Disease Relevance 0.33 Pain Relevance 0.24
The original concept of lymphoid depletion in LT was described by Starzl et al. [84].
Negative_regulation (depletion) of LT
2) Confidence 0.07 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.71 Pain Relevance 0.03
The LT modifiers comprise two pharmacologic classes of compounds, the leukotriene receptor antagonists (LTRAs) and the 5-lipoxygenase (5-LO) pathway inhibitors, or otherwise known as LT biosynthesis inhibitors.
Negative_regulation (inhibitors) of LT associated with antagonist
3) Confidence 0.04 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.31 Pain Relevance 0.05
Hence, it is unknown if CSS is a direct effect of LT inhibition or if it is due to preexisting CSS being unmasked as a result of steroid withdrawal.
Negative_regulation (inhibition) of LT associated with syndrome and withdrawal
4) Confidence 0.03 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 1.88 Pain Relevance 0.17
In addition, using LT modifiers in patients treated with high-dose (> 660 ?
Negative_regulation (using) of LT
5) Confidence 0.03 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.60 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox